Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Cetuximab Injection (HC034S) Versus Erbitux in Healthy Male Subjects
NCT07813468Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HC034S in colorectal cancer (CRC) and head and neck cancer (HNC) (2 arms). Primary endpoint: Area under the serum concentration-time curve from time 0 to infinity at Day 29. Started Sep 2026; status: recruiting.
02
Drugs
HC034S
03
Conditions
colorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07813468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813468.